drugmaker - International Biopharmaceutical Industry

news

‘We have to make a stand’: Biotech leaders vow to break ties with Russia over Ukraine war

Hundreds of biotech leaders are pledging to stop working with Russian companies and to reject investment from Russian funds in response to the country's invasion of U...

4 March 2022 news Biotech | drugmaker

Continue Reading →

news

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Final study results show Pfizer's experimental COVID-19 pill remained as effective as indicated by preliminary data last month, a major relief after promising data fo...

15 December 2021 news COVID-19 pill | data

Continue Reading →

news

Lilly deepens research ties in China with biotech deal

Lilly's deal with Regor is another example of large pharmaceutical companies in the U.S. and Europe showing interest in Chinese biotechs for their research, rather th...

13 December 2021 news Amgen | Chinese biotech

Continue Reading →

news

Martin Shkreli’s former company to pay $40M in settlement over drug price hikes

Shkreli became a symbol of pharmaceutical greed after his company, formerly Turing Pharmaceuticals, bought Daraprim in 2015 and then raised the price to $750 a tablet...

10 December 2021 news Daraprim | drug price

Continue Reading →

news

Neurocrine stocks up on a biotech’s psychiatric drugs

Neurocrine is perhaps best known for its work in movement disorders and women's health, having developed approved medications for tardive dyskinesia and the pain asso...

26 November 2021 news drugmaker | endometriosis

Continue Reading →

news

Takeda wins US approval for new CMV treatment

Livtencity is part of the first wave of new products Takeda hopes will reposition the company as a top player in the pharmaceutical industry for years to come. Earlie...

26 November 2021 news CMV | drugmaker

Continue Reading →

news

Vertex aligns with another CRISPR gene editing startup

Mammoth's evolution into a drugmaker appears to be paying off. Three years ago, the company formed with a plan to use CRISPR gene editing to detect and diagnose dise...

29 October 2021 news CRISPR | drugmaker

Continue Reading →

news

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

In some ways, AstraZeneca's COVID-19 response has been as good as any in the biopharmaceutical industry. The British drugmaker licensed and developed an effective CO...

15 October 2021 news AstraZeneca | AZD7442

Continue Reading →

news

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Merck’s filing comes less than two weeks after the drugmaker showed molnupiravir lowered the risk of hospitalization or death by roughly 50% in a Phase 3 trial, a res...

15 October 2021 news clinical trial | COVID-19

Continue Reading →

news

Gene therapy developer gets chance at a comeback with Pfizer deal

Voyager's first generation of gene therapies for ALS, Parkinson's and Huntington's disease, all now discontinued, relied on a direct infusion into brain tissue, an in...

8 October 2021 news ALS | drugmaker

Continue Reading →

Current Edition

Upcoming Events

Advertisement

‘We have to make a stand’: Biotech leaders vow to break ties with Russia over Ukraine war

In final analysis, Pfizer’s COVID-19 pill remains highly effective

Lilly deepens research ties in China with biotech deal

Martin Shkreli’s former company to pay $40M in settlement over drug price hikes

Neurocrine stocks up on a biotech’s psychiatric drugs

Takeda wins US approval for new CMV treatment

Vertex aligns with another CRISPR gene editing startup

AstraZeneca builds case for long-acting COVID-19 drug, but is it too late?

Merck, Ridgeback seek US clearance of first oral COVID-19 drug

Gene therapy developer gets chance at a comeback with Pfizer deal

International Biopharmaceutical Industry